Celcuity Inc.: Form 10-K for the period ended Dec 31, 2018
Filed with the SEC on Mar 1, 2019 and accepted by EDGAR at Mar 1, 2019, 16:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2018-01-01 to 2018-12-31 | $6.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2018-01-01 to 2018-12-31 | −$7.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2018-01-01 to 2018-12-31 | $111 | us-gaap:InterestExpense |
| Income tax | 12 months2018-01-01 to 2018-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2018-01-01 to 2018-12-31 | −$7.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2018-01-01 to 2018-12-31 | −$0.74 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2018-01-01 to 2018-12-31 | −$6.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2018-01-01 to 2018-12-31 | $629.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2018-12-31 | $15.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-12-31 | $25.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2018-12-31 | $26.0m | us-gaap:Assets |
| Current liabilities | At period end2018-12-31 | $662.3k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2018-12-31 | $682.2k | us-gaap:Liabilities |
| Shareholders' equity | At period end2018-12-31 | $25.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001144204-19-011631. Last ingested by Listed: Nov 5, 2026, 20:37 ET. Listed shows no prices and gives no investment advice.